14.98
Denali Therapeutics Inc stock is traded at $14.98, with a volume of 1.19M.
It is down -2.54% in the last 24 hours and up +5.57% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$15.37
Open:
$15.42
24h Volume:
1.19M
Relative Volume:
0.63
Market Cap:
$2.19B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-5.2561
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-1.58%
1M Performance:
+5.57%
6M Performance:
+17.95%
1Y Performance:
-46.50%
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DNLI
Denali Therapeutics Inc
|
14.98 | 2.25B | 340.81M | -419.65M | -402.10M | -2.85 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-07-25 | Resumed | Morgan Stanley | Overweight |
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Jan-07-25 | Initiated | Robert W. Baird | Outperform |
Jan-03-25 | Initiated | William Blair | Outperform |
Dec-16-24 | Upgrade | Stifel | Hold → Buy |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Dec-13-23 | Initiated | Citigroup | Buy |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Sep-06-23 | Initiated | B. Riley Securities | Buy |
Jan-30-23 | Initiated | SVB Securities | Outperform |
Dec-05-22 | Initiated | Cowen | Outperform |
Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
Nov-02-22 | Initiated | BofA Securities | Buy |
Jun-23-22 | Initiated | Berenberg | Buy |
Dec-10-21 | Resumed | Raymond James | Mkt Perform |
Sep-21-21 | Initiated | Oppenheimer | Outperform |
Sep-01-21 | Initiated | SMBC Nikko | Outperform |
May-18-21 | Initiated | UBS | Buy |
Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
Feb-24-20 | Initiated | Jefferies | Buy |
Feb-19-20 | Initiated | Stifel | Hold |
Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
Sep-26-19 | Initiated | Wedbush | Neutral |
Sep-13-19 | Initiated | Nomura | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jun-26-19 | Initiated | H.C. Wainwright | Buy |
Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
Nov-12-18 | Initiated | Janney | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Jan-02-18 | Initiated | Evercore ISI | Outperform |
Jan-02-18 | Initiated | Goldman | Neutral |
Jan-02-18 | Initiated | JP Morgan | Overweight |
Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) - Stock Titan
Will Denali Therapeutics Inc. stock rally after Fed decisionsStop Loss & Capital Protection Trade Alerts - newser.com
Understanding Denali Therapeutics Inc.’s price movementMarket Risk Analysis & Low Volatility Stock Suggestions - newser.com
How to forecast Denali Therapeutics Inc. trends using time seriesWeekly Trend Summary & Advanced Swing Trade Entry Alerts - newser.com
Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Tick level data insight on Denali Therapeutics Inc. volatilityTrend Reversal & Reliable Volume Spike Alerts - newser.com
Forecasting Denali Therapeutics Inc. price range with options data2025 Year in Review & Fast Entry High Yield Stock Tips - newser.com
What institutional flow reveals about Denali Therapeutics Inc.Quarterly Growth Report & Verified Swing Trading Watchlist - newser.com
Will Denali Therapeutics Inc. bounce back from current supportWeekly Trade Review & High Conviction Buy Zone Alerts - newser.com
Denali Therapeutics' (DNLI) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Is Denali Therapeutics Inc a good long term investmentFinancial Sector Performance & Start Small. End Wealthy. - earlytimes.in
What the Next Quarters Forecast Means for Beacon Trusteeship Limited InvestorsQuarterly Earnings Review & Free Tools to Find Winning Stocks - earlytimes.in
Denali Therapeutics Inc 4DN Stock Analysis and ForecastSector Performance Review & Get Free Expert Trading Recommendations - earlytimes.in
How to monitor Denali Therapeutics Inc. with trend dashboardsJuly 2025 Opening Moves & Consistent Profit Trade Alerts - newser.com
Regression analysis insights on Denali Therapeutics Inc. performanceBull Run & Consistent Return Strategy Ideas - newser.com
Should you hold or exit Denali Therapeutics Inc. nowJuly 2025 Institutional & Verified Swing Trading Watchlist - newser.com
Visual analytics tools that track Denali Therapeutics Inc. performanceTake Profit & Weekly Breakout Stock Alerts - newser.com
Is MPF Systems Limited a Smart Pick for Retirement PortfoliosStock Correlation Metrics & Build Wealth With Expert Timing Advice - earlytimes.in
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
Why Denali Therapeutics Inc. stock attracts global investorsPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-03 02:14:22 - newser.com
Published on: 2025-10-03 01:11:36 - newser.com
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation - 富途牛牛
Denali Therapeutics (NASDAQ:DNLI) Trading 7.4% HigherHere's What Happened - MarketBeat
What drives Denali Therapeutics Inc 4DN stock priceSector Rotation Strategies & Low Risk Trading Growth - earlytimes.in
Published on: 2025-09-30 04:04:18 - newser.com
Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News - Yahoo Finance
Published on: 2025-09-29 05:10:38 - newser.com
What drives Denali Therapeutics Inc stock priceSwing Trading Ideas & Low Risk Wealth Plans - earlytimes.in
What analysts say about Denali Therapeutics Inc stockGlobal Market Influence & Small Investment Capital Tips - earlytimes.in
Denali Therapeutics Inc Stock Analysis and ForecastSector Leadership Analysis & Free Get High Potential Alerts - earlytimes.in
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):